Biophytis Stock Rises 10.22% Following Announcement of a Joint Venture in Hong Kong
The French biotech company reacts sharply mid-session after formalizing an Asian partnership around its flagship drug candidate. The stock, which has been heavily shaken in recent months, attempts a technical reaction from rock-bottom levels.
A Surge of Over 10% Backed by the Asian Expansion of BIO101
Biophytis stock increased by 10.22% to €0.0205 during the session, after a volatile day marked by a dip below its support level at €0.02, before rebounding above it. This movement coincided with the announcement on Tuesday, June 2, 2026, of the submission of the registration dossier for the joint venture Biophytis Biopharmaceutical Holding LTD with Ronghui Renhe Life Technology. The stated goal is to accelerate the development and commercialization of BIO101 for sarcopenia in Asian markets. For a stock that has fallen into penny stock territory, the opening of a structured regional outlet provides a tangible operational signal.
A Technical Rebound That Does Not Conceal the Collapse of the Stock Over a Year
Today's surge remains anecdotal compared to the stock's trajectory, which has fallen 84.49% over one year and 60.65% over three months. The price is far below its 200-day moving average (€0.08), with a negative gap of more than 74%, although it has just moved back above its short-term moving averages MM20 and MM50, both at €0.02. The RSI at 44 remains neutral and does not confirm a reversal in dynamics at this stage. The one-month volatility is at an extreme level of 133, illustrating the amplitude of fluctuations on penny stock prices. The support at €0.02, tested and then briefly breached during the session, remains the pivot threshold to watch going forward.
